Credit: Insilico Medicine,Inc.
Wednesday, Aug. 16, 2017, Baltimore, Md. – Insilico Medicine, a Baltimore-based company at the forefront of artificial intelligence (AI) research for drug discovery, biomarker development and aging research announced today that it has formed a collaboration with GSK to explore how Insilico's AI capability can enhance its drug discovery process. The collaboration has been established following the successful completion by Insilico of a series of pilot challenges. As a first stage of the collaboration, GSK will evaluate Insilico's technology in the identification of novel biological targets and pathways of interest to GSK.
"We are delighted to be working with the Insilico team, as they have exhibited curiosity, agility and AI expertise that we value," said John Baldoni, Senior Vice President, Platform Technology Sciences at GSK. "GSK recently established a drug discovery unit to explore how this rapidly developing field might drive drug discovery at a higher velocity, with greater precision and at a reduced cost. The collaboration with Insilico represents one of several approaches we are exploring to take advantage of emerging technology that might make us more effective and efficient, always keeping in mind the patients who need new medicines."
"In our opinion, GSK is one of the most innovative science-led healthcare companies, which realized the potential of artificial intelligence technology early and has demonstrated its ability to partner with innovative startups in the field. We are delighted to collaborate with arguably, some of the world's best scientists on chronic diseases with unmet need," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, Inc.
###
About Insilico Medicine, Inc.
Insilico Medicine, Inc. is the next-generation artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia, and the UK hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and biomarker development for age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, ALS, metabolic diseases, sarcopenia, and geroprotector discovery. Through its Pharma.AI division, the company provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies. In 2017 NVIDIA selected Insilico as one of the top 5 AI companies for social impact.
For more information please contact:
Qingsong Zhu, PhD
Email: [email protected]
Media Contact
Qingsong Zhu
[email protected]
443-451-7212
@InSilicoMeds
http://www.insilicomedicine.com
